Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Keryx Biopharmaceuticals (Nasdaq: KERX) is trading at unusually high volume Friday with 8.8 million shares changing hands. It is currently at two times its average daily volume and trading down 67 cents (-7.4%) at $8.41 as of 10:45 a.m. ET.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.